2024
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2021
Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Scientific Reports 2021, 11: 12180. PMID: 34108586, PMCID: PMC8190256, DOI: 10.1038/s41598-021-91852-6.Peer-Reviewed Original ResearchConceptsLead-time biasNational Lung Screening TrialStage shiftStage IALife expectancyCancer patientsLung cancerCalendar yearNationwide cancer registryBenefits of screeningLung cancer patientsReal-world studyLung cancer diagnosisMean life expectancyTomography screeningCancer RegistryLE gainsCancer screeningEarly diagnosisScreening TrialGeneral populationSame pathologyYounger agePathologyCancer diagnosisCost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal Of Clinical Oncology 2021, 39: 2386-2396. PMID: 34019456, PMCID: PMC10166354, DOI: 10.1200/jco.21.00831.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsTreatment strategiesRadiation treatmentDuctal carcinomaAge 40Risk reductionAdjuvant treatment strategiesGood-risk patientsLarge randomized trialsAdverse event ratesOptimal treatment strategyRelative risk reductionCohort of womenBreast cancer casesLow-value careQuality of lifeCost-effectiveness analysisBase-case resultsHormonal therapyAdjuvant treatmentMost patientsPatient ageSecondary malignanciesRandomized trialsRecurrence rateEnd-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis
Davidoff AJ, Canavan ME, Prsic E, Saphire M, Wang SY, Presley CJ. End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis. Supportive Care In Cancer 2021, 29: 3921-3932. PMID: 33389087, DOI: 10.1007/s00520-020-05964-2.Peer-Reviewed Original ResearchConceptsCancer-directed therapySymptom management servicesLung cancerMedicare beneficiariesCare contentYounger ageEarlier hospice enrollmentLife care patternsLung cancer decedentsPercentage of patientsClaims-based analysisMethodsThis retrospective studyMost Medicare beneficiariesNonhospice settingsCancer decedentsUsual careHospice enrollmentSymptom managementRetrospective studyMedicare databaseSkilled nursingHigh comorbidityCare intensityMedicare claimsMultinomial logistic regression
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsTreatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan
Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLOS ONE 2020, 15: e0240542. PMID: 33052942, PMCID: PMC7556438, DOI: 10.1371/journal.pone.0240542.Peer-Reviewed Original ResearchRacial and Ethnic Disparities in Population-Level Covid-19 Mortality
Gross CP, Essien UR, Pasha S, Gross JR, Wang SY, Nunez-Smith M. Racial and Ethnic Disparities in Population-Level Covid-19 Mortality. Journal Of General Internal Medicine 2020, 35: 3097-3099. PMID: 32754782, PMCID: PMC7402388, DOI: 10.1007/s11606-020-06081-w.Peer-Reviewed Original ResearchGeographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study.
Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. Journal Of The National Comprehensive Cancer Network 2020, 18: 729-736. PMID: 32502978, DOI: 10.6004/jnccn.2020.7529.Peer-Reviewed Original ResearchConceptsHospital referral regionsCurative treatmentHepatocellular carcinomaIncidence of HCCCox proportional hazards modelSEER-Medicare studyPercutaneous ethanol injectionHepatitis B virusProportional hazards modelMore comorbiditiesSurgical resectionSurvival benefitTreatment patternsSEER-MedicareB virusRadiofrequency ablationEthanol injectionTreatment utilizationReferral regionsBetter survivalLower riskHazards modelPatientsSurvivalTreatmentAssociations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration
Hung P, Hsu SH, Wang SY. Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration. Value In Health 2020, 23: 697-704. PMID: 32540226, DOI: 10.1016/j.jval.2020.01.021.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseCongestive heart failureEOL expendituresHospice staysEnd Results-Medicare dataLonger hospice staysObstructive pulmonary diseaseMonths of lifeDays of lifeDistinct disease trajectoriesPatient disease groupsCancer decedentsDifferential associationsHeart failureAggressive endPulmonary diseaseHospice lengthMedical covariatesCancer patientsHospice useDisease groupClinical conditionsLife careDisease trajectoriesPatientsSevere functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer
Presley CJ, Canavan M, Wang SY, Feder SL, Kapo J, Saphire ML, Sheinfeld E, Kent EE, Davidoff AJ. Severe functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer. Journal Of Geriatric Oncology 2020, 11: 960-968. PMID: 32169548, PMCID: PMC7346676, DOI: 10.1016/j.jgo.2020.02.006.Peer-Reviewed Original ResearchConceptsSevere functional limitationsCo-occurring symptomsFunctional limitationsOlder adultsPrescription medicationsEmotional distressOlder adult Medicare beneficiariesAdult Medicare beneficiariesPrescription claims dataStage IV diseaseSupportive care needsMultivariable logistic regressionPrescription medication useMedicare Part D enrollmentPart D enrollmentCertain cancer typesMedication useLung cancerClaims dataPainMedicare beneficiariesCare needsFunctional independenceParticipant characteristicsCancerGlobal reach of ageism on older persons’ health: A systematic review
Chang ES, Kannoth S, Levy S, Wang SY, Lee JE, Levy BR. Global reach of ageism on older persons’ health: A systematic review. PLOS ONE 2020, 15: e0220857. PMID: 31940338, PMCID: PMC6961830, DOI: 10.1371/journal.pone.0220857.Peer-Reviewed Original ResearchConceptsSystematic reviewOlder personsHealth outcomesOlder persons' healthPrevious systematic reviewWorse health outcomesComprehensive systematic reviewAdverse health effectsRace/ethnicityStudy protocolStudy qualityEvidence of ageismGreater prevalenceHealth consequencesLiterature searchSystematic searchHealth effectsHealth domainsStandardized toolsPerson's healthPrevalenceHealthFull reviewOutcomesSignificant findings
2019
“Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer
Wang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer. Journal Of Geriatric Oncology 2019, 11: 850-859. PMID: 31899199, PMCID: PMC7263974, DOI: 10.1016/j.jgo.2019.12.010.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerRisk calculatorLocal recurrenceBreast cancerOlder womenTumor characteristicsBreast cancer-specific outcomesReceipt of radiotherapyCancer-specific outcomesEarly breast cancerIndividual patient's riskBenefits of radiotherapyAdvisory CommitteeLife expectancyOnline risk calculatorLong-term survivalShared decision makingBenefit of RTOlder adult womenRadiotherapy statusCause mortalityOverall survivalRecurrence reductionFunctional statusPatient riskIncome disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups
Killelea BK, Herrin J, Soulos PR, Pollack CE, Forman HP, Yu J, Xu X, Tannenbaum S, Wang SY, Gross CP. Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups. Breast Cancer 2019, 27: 381-388. PMID: 31792804, PMCID: PMC7512133, DOI: 10.1007/s12282-019-01028-4.Peer-Reviewed Original ResearchConceptsPhysician peer groupsLow-income patientsNeedle biopsyOdds ratioHigh-income patientsBreast cancer surgeryMethodsThe SurveillanceCancer surgeryIncome patientsMedicare databaseBiopsy patientsMedicare beneficiariesPatientsBiopsyLow incomeGroupDisparitiesReceiptEnd resultHigher incomeSurgeryPeer groupEpidemiologyFurther workGroup-level effectsA Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management
Kunst NR, Alarid-Escudero F, Paltiel AD, Wang SY. A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. Value In Health 2019, 22: 1102-1110. PMID: 31563252, PMCID: PMC7343670, DOI: 10.1016/j.jval.2019.05.004.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerObservational studyBreast cancerLow-risk early-stage breast cancerHormone receptor-positive early-stage breast cancerPredictive valueLow-risk womenProspective observational studyHigh-risk womenRetrospective observational studyBreast cancer managementQuality-adjusted life yearsCost-effectiveness findingsTraditional risk predictionAdjuvant chemotherapyChemotherapy useAlternative study designsOncotype DXCancer managementClinical utilityCurrent evidenceInsufficient evidenceLife yearsRoutine useStudy designIncorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal Of The National Comprehensive Cancer Network 2019, 17: 39-46. PMID: 30659128, DOI: 10.6004/jnccn.2018.7077.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClinical Decision-MakingConnecticutCost-Benefit AnalysisDecision Support TechniquesFemaleGene Expression ProfilingGenetic TestingHumansMarkov ChainsMastectomyMiddle AgedModels, StatisticalNeoplasm Recurrence, LocalPrevalencePrognosisQuality-Adjusted Life YearsRisk AssessmentConceptsIncremental cost-effectiveness ratioClinical risk groupsQuality-adjusted life yearsHigh-risk groupLow-risk groupOncotype DXRisk groupsBreast cancerLymph node-negative breast cancerDifferent clinical risk groupsLow-risk breast cancerNode-negative breast cancerIntermediate-risk groupRecurrence score (RS) distributionConnecticut Tumor RegistryER-positive diseaseUS payer perspectivePopulation-based dataCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness analysisODX resultsClinical characteristicsMost patientsPatient ageRacial Differences in Health Care Transitions and Hospice Use at the End of Life
Wang SY, Hsu SH, Aldridge MD, Cherlin E, Bradley E. Racial Differences in Health Care Transitions and Hospice Use at the End of Life. Journal Of Palliative Medicine 2019, 22: 619-627. PMID: 30615546, PMCID: PMC6533794, DOI: 10.1089/jpm.2018.0436.Peer-Reviewed Original ResearchConceptsHealth care transitionCare transitionsEnd of lifeHospice enrollmentHospice useLife careEthnic differencesAfrican AmericansRetrospective cohort studyMonths of lifeRace/ethnic groupsPatterns of endHospice disenrollmentCohort studyNonwhite patientsWhite patientsHospice enrolleesRacial/Ethnic DifferencesMedicare beneficiariesHospice usersDisenrollment ratesMean numberRacial differencesCareAsian Americans
2018
Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality
Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber AL, Davidoff AJ, Sedghi T, Gross CP. Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Research And Treatment 2018, 172: 453-461. PMID: 30099634, PMCID: PMC6193824, DOI: 10.1007/s10549-018-4919-3.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryBreast cancer mortalitySubsequent mastectomyCancer mortalityPre-operative MRIBreast cancerSubgroup analysisStage I/II breast cancerEnd Results-Medicare datasetPreoperative breast magnetic resonanceEarly-stage breast cancerMagnetic resonance imaging useReceipt of radiotherapyBreast magnetic resonanceClinical outcomesCox regressionResultsOur sampleImproved outcomesAdjusted ratesMRI useOlder womenLower riskMastectomyImaging useRadiotherapyCost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. Journal Of Clinical Oncology 2018, 36: 1619-1627. PMID: 29659329, PMCID: PMC5978470, DOI: 10.1200/jco.2017.76.5941.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisChemotherapy useBreast cancerEarly-stage breast cancerStudy designIncremental cost-effectiveness ratioODX recurrence scoreHigh-risk patientsLow-risk patientsRisk of biasCost-effectiveness ratioCost-effectiveness estimatesIndustry fundingDistant recurrenceIndustry-funded studiesClinical characteristicsTumor characteristicsRecurrence scoreChemotherapy decisionsScore groupClinical practiceSystematic reviewODXPatientsCancerAssociations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ
Killelea BK, Long JB, Dang W, Mougalian SS, Evans SB, Gross CP, Wang SY. Associations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ. Annals Of Surgical Oncology 2018, 25: 1521-1529. PMID: 29516364, PMCID: PMC5928184, DOI: 10.1245/s10434-018-6410-0.Peer-Reviewed Original ResearchConceptsSentinel lymph node biopsyBreast-conserving surgeryLymph node biopsySLNB useNode biopsyWound infectionDuctal carcinomaUse of SLNBEnd Results-Medicare datasetIncidence of complicationsShort-term complicationsMonths of diagnosisOlder patientsSubsequent mastectomyInitial treatmentResultsOur sampleConsensus guidelinesHigh riskOlder womenComplicationsMultivariate analysisPatientsWomenDCISMastectomy
2017
Associations of Hospice Disenrollment and Hospitalization With Continuous Home Care Provision
Wang SY, Dang W, Aldridge MD, Canavan M, Cherlin E, Bradley E. Associations of Hospice Disenrollment and Hospitalization With Continuous Home Care Provision. Medical Care 2017, 55: 848-855. PMID: 28692573, PMCID: PMC5554087, DOI: 10.1097/mlr.0000000000000776.Peer-Reviewed Original Research